PWMA
SPRY icon

Pension & Wealth Management Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Pension & Wealth Management Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73
Closed -$1.07K – 497
2024
Q3 		$1.07K Buy
+73
New +$868 ﹤0.01% 340

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Pension & Wealth Management Advisors's SPRY Position: Q4 2024 in Review

Pension & Wealth Management Advisors sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 73 shares — an estimated $1.07K sold.

Pension & Wealth Management Advisors first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $1.07K in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Pension & Wealth Management Advisors reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Pension & Wealth Management Advisors sold 73 ARS Pharmaceuticals shares in Q4 2024, an estimated $1.07K.
  • Pension & Wealth Management Advisors first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Pension & Wealth Management Advisors's ARS Pharmaceuticals position peaked at $1.07K in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Pension & Wealth Management Advisors's 13F filing for Q4 2024, filed 7 Aug 2026.